Skip to main content
. 2020 Sep 11;13:9043–9057. doi: 10.2147/OTT.S262084

Table 3.

Univariate and Multivariate Cox Models for PFS in Training Cohort

Variables Uni HR 95% CI p-value Multi HR 95% CI p-value
Age
 <60 1
 ≥60 0.98 0.73–1.31 0.87
Marital
 Married 1
 Unmarried 1.29 0.57–2.93 0.54
BMI
 BMI<18.5 1
 18.5≥BMI<25 1.21 0.56–2.61
 BMI≥25 1.04 0.47–2.25 0.55
Sex
 Male 1
 Female 0.78 0.54–1.12 0.17
Smoking History
 No 1
 Yes 1.08 0.79–1.47 0.64
Smoking Index
 <800 1
 ≥800 1.16 0.86–1.57 0.33
KPS
 ≥90 1
 <90 1.03 0.76–1.39 0.85
T Stage
 T1-T2 1 1
 T3-T4 1.40 1.03–1.91 0.03 1.33 0.95–1.85 0.097
N Stage
 N0-N2 1 1
 N3 1.62 1.20–2.20 0.002 1.41 1.03–1.93 0.034
Brain Metastasis
 No 1
 Yes 0.98 0.71–1.35 0.90
Liver Metastasis
 No 1
 Yes 1.31 0.95–1.79 0.095
Bone Metastasis
 No 1
 Yes 1.07 0.78–1.47 0.66
Thoracic Radiotherapy
 No 1 1
 Yes 0.40 0.29–0.56 <0.001 0.40 0.29–0.56 <0.001
Pre-ALB
 ≤40 1
 >40 0.85 0.61–1.18 0.33
Pre-ALP
 ≤100 1
 >100 1.22 0.90–1.65 0.20
Pre-AAPR
 ≤0.52 1
 >0.52 0.21 0.50–0.95 0.021
Post-ALB
 ≤40 1
 >40 0.60 0.60–1.12 0.21
Post-ALP
 ≤100 1
 >100 1.39 1.00–1.93 0.049
Post-AAPR
 ≤0.52 1 1
 >0.52 0.61 0.45–0.82 0.001 0.67 0.49–0.92 0.013

Abbreviations: AAPR, albumin-to-alkaline phosphatase ratio; BMI, body mass index; HR, hazard ratios; KPS, Karnofsky performance score; PFS, progression-free survival.